Linked Life Data

2804987

Source:http://linkedlifedata.com/resource/pubmed/id/2804987

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2804987rdf:typepubmed:Citationlld:pubmed
pubmed-article:2804987lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:2804987lifeskim:mentionsumls-concept:C0006826lld:lifeskim
pubmed-article:2804987lifeskim:mentionsumls-concept:C0019145lld:lifeskim
pubmed-article:2804987lifeskim:mentionsumls-concept:C0205054lld:lifeskim
pubmed-article:2804987lifeskim:mentionsumls-concept:C0016360lld:lifeskim
pubmed-article:2804987lifeskim:mentionsumls-concept:C0020811lld:lifeskim
pubmed-article:2804987lifeskim:mentionsumls-concept:C1521750lld:lifeskim
pubmed-article:2804987lifeskim:mentionsumls-concept:C0598717lld:lifeskim
pubmed-article:2804987lifeskim:mentionsumls-concept:C0920321lld:lifeskim
pubmed-article:2804987lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:2804987lifeskim:mentionsumls-concept:C1705938lld:lifeskim
pubmed-article:2804987lifeskim:mentionsumls-concept:C1527178lld:lifeskim
pubmed-article:2804987pubmed:issue22lld:pubmed
pubmed-article:2804987pubmed:dateCreated1989-12-11lld:pubmed
pubmed-article:2804987pubmed:abstractTextEighteen patients with hepatic metastases primarily from colorectal carcinoma were treated on a phase I protocol employing hepatic artery infusion (HAI) of 5-fluorouracil (FUra) and 5-iodo-2'-deoxyuridine (IdUrd) via implantable infusion pump. Patients received a 14-day continuous HAI of 300 mg/day FUra. During days 8-14 of therapy, patients received IdUrd as a separate 3-h HAI daily x 7. Treatment cycles were repeated every 28 days. IdUrd was escalated from 0.1 to 2.86 mg/kg/day x 7. Myelosuppression and stomatitis were mild and not dose limiting. Hepatotoxicity was dose limiting and similar to that reported for 5-fluoro-2'deoxyuridine alone administered as a 14-day infusion every month. One patient developed a clinical picture consistent with sclerosing cholangitis and another had biopsy-proven cholestasis and triaditis. Catheter complications occurred in 7 of 18 patients. Plasma concentrations of FUra during the 7-day continuous HAI of FUra alone were consistently either undetectable or very low (less than or equal to 0.1 microM). At level 3 (1.0 mg/kg/day IdUrd) and beyond, measurable plasma concentrations of FUra, iodouracil, and IdUrd were found at the end of the daily 3-h infusion of IdUrd. The maximum tolerated dose of IdUrd as administered in this trial is 2.2 mg/kg/day x 7 and the recommended starting dose for further clinical investigation is 1.7 mg/kg/day x 7.lld:pubmed
pubmed-article:2804987pubmed:languageenglld:pubmed
pubmed-article:2804987pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2804987pubmed:citationSubsetIMlld:pubmed
pubmed-article:2804987pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2804987pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2804987pubmed:statusMEDLINElld:pubmed
pubmed-article:2804987pubmed:monthNovlld:pubmed
pubmed-article:2804987pubmed:issn0008-5472lld:pubmed
pubmed-article:2804987pubmed:authorpubmed-author:WirtanenG WGWlld:pubmed
pubmed-article:2804987pubmed:authorpubmed-author:RamirezGGlld:pubmed
pubmed-article:2804987pubmed:authorpubmed-author:WeeseJ LJLlld:pubmed
pubmed-article:2804987pubmed:authorpubmed-author:WillsonJ KJKlld:pubmed
pubmed-article:2804987pubmed:authorpubmed-author:FischerP HPHlld:pubmed
pubmed-article:2804987pubmed:authorpubmed-author:RemickS CSClld:pubmed
pubmed-article:2804987pubmed:authorpubmed-author:BensonA...lld:pubmed
pubmed-article:2804987pubmed:authorpubmed-author:TutschK DKDlld:pubmed
pubmed-article:2804987pubmed:authorpubmed-author:AlbertiD BDBlld:pubmed
pubmed-article:2804987pubmed:authorpubmed-author:NietingL MLMlld:pubmed
pubmed-article:2804987pubmed:issnTypePrintlld:pubmed
pubmed-article:2804987pubmed:day15lld:pubmed
pubmed-article:2804987pubmed:volume49lld:pubmed
pubmed-article:2804987pubmed:ownerNLMlld:pubmed
pubmed-article:2804987pubmed:authorsCompleteNlld:pubmed
pubmed-article:2804987pubmed:pagination6437-42lld:pubmed
pubmed-article:2804987pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:2804987pubmed:meshHeadingpubmed-meshheading:2804987-...lld:pubmed
pubmed-article:2804987pubmed:meshHeadingpubmed-meshheading:2804987-...lld:pubmed
pubmed-article:2804987pubmed:meshHeadingpubmed-meshheading:2804987-...lld:pubmed
pubmed-article:2804987pubmed:meshHeadingpubmed-meshheading:2804987-...lld:pubmed
pubmed-article:2804987pubmed:meshHeadingpubmed-meshheading:2804987-...lld:pubmed
pubmed-article:2804987pubmed:meshHeadingpubmed-meshheading:2804987-...lld:pubmed
pubmed-article:2804987pubmed:meshHeadingpubmed-meshheading:2804987-...lld:pubmed
pubmed-article:2804987pubmed:meshHeadingpubmed-meshheading:2804987-...lld:pubmed
pubmed-article:2804987pubmed:meshHeadingpubmed-meshheading:2804987-...lld:pubmed
pubmed-article:2804987pubmed:meshHeadingpubmed-meshheading:2804987-...lld:pubmed
pubmed-article:2804987pubmed:meshHeadingpubmed-meshheading:2804987-...lld:pubmed
pubmed-article:2804987pubmed:meshHeadingpubmed-meshheading:2804987-...lld:pubmed
pubmed-article:2804987pubmed:meshHeadingpubmed-meshheading:2804987-...lld:pubmed
pubmed-article:2804987pubmed:meshHeadingpubmed-meshheading:2804987-...lld:pubmed
pubmed-article:2804987pubmed:year1989lld:pubmed
pubmed-article:2804987pubmed:articleTitlePhase I trial of hepatic artery infusion of 5-iodo-2'-deoxyuridine and 5-fluorouracil in patients with advanced hepatic malignancy: biochemically based combination chemotherapy.lld:pubmed
pubmed-article:2804987pubmed:affiliationUniversity of Wisconsin Clinical Cancer Center, Madison.lld:pubmed
pubmed-article:2804987pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2804987pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed